Clinical trial · Observational
Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Platinum-sensitive is an important basis for the treatment of recurrent epithelial ovarian cancer (EOC) without effective methods to predict.We aimed to develop and validate the EOC deep learning system to predict the platinum-sensitive of EOC patients through analysis of enhanced magnetic resonance imaging (MRI) images before initial treatment.Ninety-three EOC patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery from Sun Yat-sen Memorial Hospitalin China from January 2011 to January 2020 were enrolled. This deep-learning EOC signature achieved a high predictive power for platinum-sensitive, and the signature based on MRI whole volume is better than that on primary tumor area only.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Predictive Cancer Model | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiomic Algorithm | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- platinum-resistant group
- interventionNames
- Other: Radiomic Algorithm
- label
- platinum-sensitive group
- interventionNames
- Other: Radiomic Algorithm
Primary outcomes (1)
- measure
- Platinum sensitivity
- timeFrame
- 9 years
- description
- Platinum sensitivity
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 22 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * (1)Patients with epithelial ovarian cancer (2 )Patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery Exclusion Criteria: * Patients with epithelial ovarian cancer received less than 4 cycles platinum-based chemotherapy or no debulking surgery
References
Publications (0)
Data not yet available